Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Services

    Services

    Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read more
    Services
    Clinical Research ServicesCommercial PositioningConsultingEarly PhaseStrategic SolutionsLaboratoriesLanguage ServicesMedical ImagingReal World IntelligenceSite & Patient Solutions
    Clinical trials during COVID-19.
    COVID-19 clinical operations

    Clinical trials during COVID-19.

    Bringing the clinical trial to the patient with innovation and in-home solutions.
    Decentralised & hybrid clinical solutions

    Bringing the clinical trial to the patient with innovation and in-home solutions.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Sectors
    BiosimilarsBiotechGovernment & Public Health SolutionsMedical DevicePharmaceuticals
    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
    The IVDR journey

    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.

    Developing transformative therapies requires a flexible approach.
    Biotech

    Developing transformative therapies requires a flexible approach.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read more
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyPaediatricsRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
    Vaccines

    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Innovation

    Innovation

    We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

    Read more
    Innovation
    FIRECRESTICON Digital PlatformSafety Reporting SolutionOne SearchEvidence PlatformFLEX ADVANTAGEMedical Imaging TechnologyNONMEM ICONIKPDx-POPPubsHubSIMSICOMaster for eTMFControl TowerPrism eClinical Solution
    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
    FIRECREST

    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.

    Harmonising data and services for more integrated decentralised clinical trials.
    ICON Digital Platform

    Harmonising data and services for more integrated decentralised clinical trials.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read more
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Establishing a platform for improvement
    Diversity and inclusion in clinical trials

    Establishing a platform for improvement

    Patient focused research for better outcomes.
    Decentralised & hybrid clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    News & Events
    Press releasesIn the NewsMediakitAwardsEventsWebinarsSocial media
    Register today
    Webinar: Challenges in assessing long term effects of Covid and Covid vaccines

    Register today

    Register today
    Webinar: Rare disease week 2023 - Exploring accessibility in rare disease clinical research

    Register today

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read more
    About ICON
    Company historyICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON CARES is our commitment to making a positive impact on our people, environment and our community.
    Environmental, Social and Governance

    ICON CARES is our commitment to making a positive impact on our people, environment and our community.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 27 April 2022

    ICON reports first quarter 2022 results

    Quarter 1 adjusted revenue of $1.901.8 million representing a year on year increase of 121.6% or 125% on a constant currency basis.

  • 10 March 2022

    ICON plc to Webcast Analyst Day Meeting

    Thursday, March 17, 2022 at 12:30 ET.

  • 22 February 2022

    ICON Reports Fourth Quarter and Full Year 2021 Results

    Record net business wins in the quarter of $2,378 million; a net book to bill of 1.26. Full year net business wins of $6,958 million; a net book to bill of 1.27.

  • 18 February 2022

    ICON plc to Present at the 2022 Citi Healthcare Conference

    Thursday, February 24, 2022 at 11:45 ET.

  • 12 January 2022

    ICON Issues Financial Guidance for Full Year 2022

    Full Year 2022 adjusted earnings per share guidance in the range of $11.55 - $11.95, representing growth of 21 – 23% over Full Year 2021 adjusted earnings per share guidance.

  • 5 January 2022

    ICON plc to Present at the 40th Annual JP Morgan Healthcare Conference

    A world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 40th Annual JP Morgan Healthcare Conference

  • 3 December 2021

    ICON named best Contract Research Organisation in latest string of awards and recognitions

    ICON and its drug and device development work continues to be recognised by peers, employees, and organisations around the globe

  • 22 November 2021

    ICON Releases Environmental, Social and Governance Report

    ICON announced the release of its 2020 Environmental, Social and Governance Report. The report looks to the future of ESG for the new ICON while highlighting advancements made in 2020.

  • 10 November 2021

    ICON announces the expansion of its Accellacare Site Network

    New partnerships increase geographical footprint, supporting more access to patients and strengthening therapeutic capability

  • 5 November 2021

    ICON plc to Present at the 30th Annual Credit Suisse Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference

    Tuesday, November 9, 2021 at 8.50am ET

  • 1
  • 2
  • 3
  • 4
  • 5
  • ...
  • 15
In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON Spokespeople
  • Awards
  • Events
    • Industry events
      • SCOPE 2023
      • ASCO 2023
    • Webinars
    • Workshops
    • Financial Times Global Pharmaceutical and Biotechnology Conference
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What’s happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Services
  • Insights
  • Innovation
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Social media dashboard
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2023 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies
  • International Transfers

Connect with us

Contact usSubmit proposal requestUpdate Email PreferencesGlobal office locatorICON on social media